Goldman Sachs Stays Sidelined on Sage Therapeutics (SAGE) Following SAGE-178 Miss on Phase 2 Parkinson's Study
Tweet Send to a Friend
Goldman Sachs analyst Salveen Richter reiterated a Neutral rating and $28.00 price target on Sage Therapeutics (NASDAQ: SAGE).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
